Patient Safety, Risk Management, and Continuous Quality Improvement
Safety is designed, not hoped for
Patient safety in compounding rests on systems: standardized concentrations and bases, limited formularies, ready-to-use products, barcode verification, smart-pump libraries, independent double checks for high-alert medications, and removal of error-prone abbreviations. Error reporting must be nonpunitive at the front line - a just culture distinguishes human error, at-risk behavior, and reckless behavior - because reporting is the raw material of improvement.
Tools: root cause analysis for a serious event or a cluster; failure mode and effects analysis (FMEA) prospectively, scoring severity × occurrence × detectability and acting on the highest scores; plan-do-study-act cycles for small tests of change; and trend review of deviations, complaints, and monitoring results. Traceability is a safety function: lot numbers must allow a recall to reach every patient who received a CSP.
Traps: believing more double checks fix a weak process; treating FMEA detectability as reliable when the failure mode is invisible; measuring success by the absence of reported errors rather than by reporting rates and process compliance.
Worked example: three look-alike vials of high-alert drugs sit side by side. Rather than adding a fourth check, separate the storage, apply tall-man lettering, restrict to one concentration per bin, then audit.
Rule of thumb: if a failure can be designed out, do not rely on a human to catch it.